AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPTHEA LTD

0.600

+0.000

Volume:- -

Turnover:- -

Market Cap:738.77M

PE:-1.38

High:0.600

Open:0.600

Low:0.600

Close:0.600

Loading ...

Overview Company News Filings

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Raises 'Going Concern' Doubts

MT Newswires Live

Opthea’s Phase 3 trial results fail to help patients, future of company at risk

The Market Herald

Monday’s HotCopper Trends: Opthea strife, Errawarra jumps on acquisitions, Memphasys best-in-class trial results | March 21, 2025

The Market Herald

BRIEF-Opthea Say Coast Phase 3 Trial Fails To Meet Primary Endpoint

Opthea Ltd - Coast Phase 3 Trial Fails to Meet Primary Endpoint

THOMSON REUTERS

Wednesday’s HotCopper Trends: Imugene scores FDA tick, Arizona kicks off share purchase plan | March 19, 2025

The Market Herald

ASX Market Open: Bounceback to survive a second day Down Under | March 18, 2025

The Market Herald

Trading in Opthea Halted Ahead of Update on Wet AMD Study

Monday’s HotCopper Trends: Spartan and Ramelius merger, Arizona capital raise | March 17, 2025

The Market Herald

Opthea Requests Trading Halt

MT Newswires Live

BRIEF-Opthea Seeks Trading Halt

Opthea Ltd - Seeks Trading Halt Pending Announcement on Top Line Results of Its Phase 3 Coast Clinical Trial

THOMSON REUTERS

Exploring Three High Growth Tech Stocks In Australia

Simply Wall St.

Opthea First Half 2025 Earnings: US$0.11 loss per share (vs US$0.17 loss in 1H 2024)

Simply Wall St.

Opthea Says Trial Data for Eye Disease Drug Candidate Published in Peer-Reviewed Journal

MT Newswires Live

Press Release: Opthea Reports Half Year Results and Business Updates

Opthea Posts Narrower Fiscal H1 Loss, Lower Revenue

MT Newswires Live

BRIEF-Opthea Says HY Loss From Ordinary Activities Before Tax Increased To $137.9 Million

Corrected-Opthea Ltd - Hy Loss From Ordinary Activities Before Tax Increased 29% to $137.9 Mln (Corrects Currency to $ From a$)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OPT.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","market":"AU","secType":"STK","nameCN":"OPTHEA LTD","latestPrice":0.6,"timestamp":1743743520000,"preClose":0.6,"halted":0,"volume":0,"delay":0,"nameEN":"OPTHEA LTD","floatShares":786004505,"shares":1231284320,"eps":-0.4354509349660765,"marketStatus":"Market Closed","change":0,"latestTime":"04-04 16:12:00 AEDT","open":0.6,"high":0.6,"low":0.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.4354509349660765,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1743984000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.6,"openAndCloseTimeList":[[1743721200000,1743742800000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","floatShares":786004505,"roa":"-73.34%","roe":"-3383.08%","lyrEps":-0.571069,"shares":1231284320,"dividePrice":0,"high":0.6,"amplitude":0,"preClose":0.6,"low":0.6,"week52Low":0.335,"pbRate":"-2.65","psRate":"2137.51","week52High":1.165,"institutionHeld":0,"latestPrice":0.6,"eps":-0.4354509349660765,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.4354509349660765,"open":0.6,"prevYearClose":0.81,"prevWeekClose":0.6,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.6,"twentyDayClose":0.7,"sixtyDayClose":0.745},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OPT.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521756759","title":"Opthea Announces COAST Phase 3 Trial Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521756759","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521756759?lang=en_us&edition=fundamental","pubTime":"2025-03-24 12:01","pubTimestamp":1742788860,"startTime":"0","endTime":"0","summary":"COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52. Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern. The global COAST Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 2 mg aflibercept, as per label, every eight weeks after a loading phase for the treatment of wet AMD. The trial did not meet its primary endpoint of mean change in best corrected visual acuity  from baseline to week 52.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-announces-coast-phase-3-040100859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Opthea Announces COAST Phase 3 Trial Topline Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1880398471.USD","LU1242518857.USD","BK4566","LU1316542783.SGD","LU1064131342.USD","BK4588","BK4612","LU0081259029.USD","LU0823434740.USD","LU2458330169.SGD","LU2250418816.HKD","LU1923623000.USD","BK4534","IE00B5949003.HKD","LU1988902786.USD","BK4543","LU2264538146.SGD","IE0009356076.USD","BK4573","GFS","LU0979878070.USD","LU1951200564.SGD","LU1803068979.SGD","IE00BMPRXN33.USD","LU0719512351.SGD","LU0889565833.HKD","LU1989764664.SGD","LU2098885051.SGD","LU0109392836.USD","LU2360106780.USD","IE0004445239.USD","OPT","BK4554","LU0642271901.SGD","BK4529","BK4585","LU1880398554.USD","LU1242518931.SGD","OPT.AU","IE00BMPRXR70.SGD","LU1852331112.SGD","LU0056508442.USD","LU0390134368.USD","LU2458330243.SGD","LU1951198990.SGD","BK4605","BK4139","LU2054465674.USD","LU0082616367.USD","BK4532"],"gpt_icon":1},{"id":"2521732916","title":"Opthea Raises 'Going Concern' Doubts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521732916","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521732916?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:36","pubTimestamp":1742783798,"startTime":"0","endTime":"0","summary":"Opthea  said its Combination OPT-302 with Aflibercept  study in patients with wet age-related Macular Degeneration, failed to meet its primary endpoint, according to a Monday filing with the Australian bourse.The biopharmaceutical company is now reviewing its obligations under its development funding agreement  with investors, the filing said.Under the DFA, Opthea could face repayment obligations of up to $680 million, if the agreement is terminated, due to factors like failure to advance its drug sozinibercept, used in the trial, the filing added.Discussions with the DFA investors are ongoing for the parties to come to an agreement, including a negotiated settlement, however, no decision has been made regarding the continuation of the trial, the company said.Given uncertainties regarding the trial and a reported $113.8 million in cash, the company added there is significant doubt about its ability to continue as a going concern.Opthea requested an extension of trading suspensions on t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","BK4139","XJO.AU","OPT","XKO.AU","BK7067","BK7508","XAO.AU"],"gpt_icon":0},{"id":"2521531157","title":"Opthea’s Phase 3 trial results fail to help patients, future of company at risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2521531157","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521531157?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:15","pubTimestamp":1742782500,"startTime":"0","endTime":"0","summary":"It mightn’t be too surprising Opthea  applied for a voluntary suspension last week ahead of Monday’s Phase 3 trial results – they throw the future of the company into question.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.“[The] COAST Phase 3 trial failed to meet primary endpoint of mean change … from baseline,” the company wrote of its retinal disease trial.The problem is, with a Development Funding Agreement backed by investors, the company is now unsure whether or not it has a future at all. Phase 3 trials are the be-all-end-all study that typically precedes an FDA approval.“In light of these matters, there remains material uncertainty as to Opthea’s ability to continue as a going concern,” Opthea wrote on Monday.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/optheas-phase-3-trial-results-fail-to-help-patients-future-of-company-at-risk-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LU1852331112.SGD","BK4566","LU0642271901.SGD","BK4534","LU0823434583.USD","LU2264538146.SGD","LU2250418816.HKD","LU2054465674.USD","BK4512","LU0198837287.USD","LU1064131342.USD","LU0823421416.USD","BK4532","BK4585","LU0082616367.USD","LU1989764664.SGD","BK4575","LU0081259029.USD","LU1951200564.SGD","LU0056508442.USD","BK4588","IE0009356076.USD","IE0004445239.USD","LU0823421333.USD","LU2458330169.SGD","OPT.AU","BK4543","BK7067","BK4139","LU0979878070.USD","BK4605","LU1303367103.USD","LU1880398471.USD","IE00BMPRXR70.SGD","LU0823434740.USD","LU1988902786.USD","LU1316542783.SGD","LU0390134368.USD","LU1923623000.USD","BK4554","IE00B5949003.HKD","LU1803068979.SGD","LU0127658192.USD","BK7508","LU0889565833.HKD","IE00BMPRXN33.USD","OPT","LU1951198990.SGD","BK4612"],"gpt_icon":1},{"id":"2521734542","title":"Monday’s HotCopper Trends: Opthea strife, Errawarra jumps on acquisitions, Memphasys best-in-class trial results | March 21, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521734542","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521734542?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:13","pubTimestamp":1742782380,"startTime":"0","endTime":"0","summary":"The ASX has been trading flat at around 7,928 points.Discretionary has been the best performing sector today, up 1%, followed by Financials, up 0.66%, and Utilities, up 0.5%.Staples has been the worst performing, down 1%, followed by Materials, down 0.9%, and Industrials, down 0.8%.Opthea  has been the most watched on HotCopper forums today and is in a trading halt. Its COAST Phase 3 trial failed to meet primary endpoint of mean change in best corrected visual acuity from baseline to Week 52. The company is now considering the overall impact of the negative trial result heading into the year.Also trending: Errawarra Resources , which has entered binding agreements to acquire 70% of the historical Elizabeth Hill Silver Project, 70% of the silver rights to the Pinderi Hills Project tenement package, and 70% of the ownership of three tenements surrounding the silver project.Rounding out the most discussed has been Memphasys , which unveiled the successful unblinding and data analysis of i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-opthea-strife-errawarra-jumps-on-acquisitions-memphasys-best-in-class-trial-results-march-21-2025-2025-03-24/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ERW.AU","MEM.AU","OPT","OPT.AU","BK7508","MEM","BK7095","BK7048","BK7067"],"gpt_icon":0},{"id":"2521735610","title":"BRIEF-Opthea Say Coast Phase 3 Trial Fails To Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2521735610","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521735610?lang=en_us&edition=fundamental","pubTime":"2025-03-24 09:14","pubTimestamp":1742778886,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Say Coast Phase 3 Trial Fails To Meet Primary EndpointMarch 24 (Reuters) - Opthea Ltd OPT.AX:COAST PHASE 3 TRIAL FAILS TO MEET PRIMARY ENDPOINTFurther company coverage: OPT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q503G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2521787186","title":"Opthea Ltd - Coast Phase 3 Trial Fails to Meet Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2521787186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521787186?lang=en_us&edition=fundamental","pubTime":"2025-03-24 07:42","pubTimestamp":1742773328,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250323:nFWN3Q503G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OPT.AU","BK7508"],"gpt_icon":0},{"id":"2520930569","title":"Wednesday’s HotCopper Trends: Imugene scores FDA tick, Arizona kicks off share purchase plan | March 19, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520930569","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520930569?lang=en_us&edition=fundamental","pubTime":"2025-03-19 09:57","pubTimestamp":1742349420,"startTime":"0","endTime":"0","summary":"The ASX has been trading flat at around 7,864 points.Financials has been the best performing sector, up 0.3%, followed by Materials, up 0.15% and Energy, up 0.1%.Utilities has been the worst performer, down 1.1%, followed by Industrials and Staples, both down 0.55%.Opthea  has been the most watched on HotCopper forums today. The company is in a voluntary suspension pending the release of top line results of its COAST clinical trial.Also trending Imugene  has revealed the US Food and Drug Administration has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel , for the treatment of relapsed or refractory diffuse large B-cell lymphoma .Rounding out the most discussed is Arizona Lithium  after kicking off a share purchase plan to raise $2 million to advance the Prairie project.You’re up to date, see you later for market close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/wednesdays-hotcopper-trends-imugene-scores-fda-tick-arizona-kicks-off-share-purchase-plan-march-19-2025-2025-03-19/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BK7095","BK7507","BK7504","IMU.AU","OPT.AU","AZL.AU","BK7067"],"gpt_icon":0},{"id":"2520138689","title":"ASX Market Open: Bounceback to survive a second day Down Under | March 18, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520138689","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520138689?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:10","pubTimestamp":1742245800,"startTime":"0","endTime":"0","summary":"Week 12’s global rally is holding firm early this Tuesday morning, with ASX 200 futures pointing to a +0.83% gain  when trade begins at 10am in Sydney.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.It’s not the only rally everyone’s watching either – after nudging around the historic high several times, gold is trading above $3,000 an ounce today for the very first time. For many, the safe haven asset has been seen as a perfect way to dodge all the uncertainty fuelled by Trump and his tariffs in the short term.Though there has been a rush towards gold, stocks have enjoyed a green bounceback through Monday and Tuesday this week too: Today, all three major U.S. indices returned some recent losses. The Dow Jones led the way, up 0.8%.So too Mineral Resources  after the leading miner just scored a “buy” upgrade from UBS that sparked a lithium and battery metals stock rally.That’s Market","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-bounceback-to-survive-a-second-day-down-under-march-18-2025-2025-03-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","MIN.AU","NAB.AU","BK7507","BK7504","BK7095","BK7511","WBC.AU","OPT.AU","BK7067","BK7135"],"gpt_icon":0},{"id":"2520795515","title":"Trading in Opthea Halted Ahead of Update on Wet AMD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2520795515","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520795515?lang=en_us&edition=fundamental","pubTime":"2025-03-17 23:26","pubTimestamp":1742225160,"startTime":"0","endTime":"0","summary":"Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD.In a filing with the Australian Securities Exchange Monday, Opthea requested the trading halt pending an announcement related to top-line results of a Phase 3 study of sozinibercept in combination with aflibercept in wet AMD, an eye condition that causes blurred vision or reduced central vision.The ASX said the halt will remain in place until the start of trading Wednesday unless Opthea issues an announcement sooner.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4512","BK4573","LU0127658192.USD","LU0823421416.USD","BK4529","LU2360106780.USD","LU0082616367.USD","IE0009356076.USD","LU1303367103.USD","IE00B5949003.HKD","LU0109392836.USD","BK7067","GFS","LU0198837287.USD","LU2250418816.HKD","LU1923623000.USD","LU1988902786.USD","OPT.AU","IE0004445239.USD","LU0823434740.USD","LU0390134368.USD","LU0889565833.HKD","LU1951200564.SGD","LU0823421333.USD","OPT","BK4614","LU1242518857.USD","LU1316542783.SGD","BK4534","BK4554","BK4588","LU0979878070.USD","LU2458330243.SGD","LU2054465674.USD","LU1242518931.SGD","BK4585","LU0056508442.USD","LU0823434583.USD","BK4566","LU0642271901.SGD","LU2264538146.SGD","LU1803068979.SGD","BK4605","BK4612","LU1880398471.USD","LU1852331112.SGD","BK4141","BK4543"],"gpt_icon":1},{"id":"2520559489","title":"Monday’s HotCopper Trends: Spartan and Ramelius merger, Arizona capital raise | March 17, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520559489","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520559489?lang=en_us&edition=fundamental","pubTime":"2025-03-17 10:32","pubTimestamp":1742178720,"startTime":"0","endTime":"0","summary":"The ASX has been up 0.62% at 7,837 points, following Wall Street’s Friday lead.It’s a sea of green today and Materials has been the best performing sector, up 1.55%, followed by Energy, up 1%, and Real Estate, up 0.66%.Health Care is the one and only sector in the red, down 0.25%.Spartan Resources  has been the most watched on HotCopper forums today, with the company in advanced merger talks with Ramelius Resources . The deal is slated to be announced to the ASX as early as next week.Also trending: Opthea  has been placed in a trading halt pending a material announcement regarding top line results of its COAST  clinical trial.Rounding out the most discussed has been Arizona Lithium , which entered a trading halt pending a capital raising announcement.Meet GeoGeorge:The HotCopper poster so accurate he got hired as an analyst. The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-spartan-and-ramelius-merger-arizona-capital-raise-march-17-2025-2025-03-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7104","AZL.AU","BK7506","SPR.AU","BK7095","OPT.AU","BK7067","BK7508","SPAQ.U","RMS.AU","BK7507","BK7504"],"gpt_icon":0},{"id":"2520629580","title":"Opthea Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2520629580","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520629580?lang=en_us&edition=fundamental","pubTime":"2025-03-17 07:45","pubTimestamp":1742168746,"startTime":"0","endTime":"0","summary":"Opthea  requested that its securities be placed in trading halt until an announcement related to results of its Phase 3 Combination OPT-302 with Aflibercept Study  clinical trial is made, according to a Monday filing with the Australian bourse.The trading halt will remain in place until the start of trading on March 19 or when the company makes the announcement about the COAST results, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT","BK7508","OPT.AU","BK4139","BK7067"],"gpt_icon":0},{"id":"2520581786","title":"BRIEF-Opthea Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2520581786","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520581786?lang=en_us&edition=fundamental","pubTime":"2025-03-17 05:57","pubTimestamp":1742162230,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Seeks Trading HaltMarch 17 (Reuters) - Opthea Ltd OPT.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON TOP LINE RESULTS OF ITS PHASE 3 COAST CLINICAL TRIALFurther company coverage: OPT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250316:nFWN3PY00H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2520558193","title":"Opthea Ltd - Seeks Trading Halt Pending Announcement on Top Line Results of Its Phase 3 Coast Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520558193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520558193?lang=en_us&edition=fundamental","pubTime":"2025-03-17 05:41","pubTimestamp":1742161316,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250316:nFWN3PY00H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2518779823","title":"Exploring Three High Growth Tech Stocks In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2518779823","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518779823?lang=en_us&edition=fundamental","pubTime":"2025-03-12 03:05","pubTimestamp":1741719951,"startTime":"0","endTime":"0","summary":"In the current Australian market landscape, the ASX200 has recently experienced a downturn, closing down 0.9% at 7,890 points with IT being the worst-performing sector. Despite this challenging environment, identifying high-growth tech stocks requires careful consideration of their innovation potential and resilience in navigating volatile conditions.Click here to see the full list of 52 stocks from our ASX High Growth Tech and AI Stocks screener.Operations: The company generates revenue primarily from the provision of backup services, amounting to A$41.17 million.Click here to discover the nuances of Dropsuite with our detailed analytical health report.Overview: Nuix Limited offers investigative analytics and intelligence software solutions across various regions including the Asia Pacific, the Americas, Europe, the Middle East, and Africa with a market cap of approximately A$1.13 billion.Operations: Nuix generates revenue primarily from its Software & Programming segment, which accou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-three-high-growth-tech-190551662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPT","OPT.AU","BK4139","NXL.AU","DSE.AU"],"gpt_icon":0},{"id":"2517929091","title":"Opthea First Half 2025 Earnings: US$0.11 loss per share (vs US$0.17 loss in 1H 2024)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517929091","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517929091?lang=en_us&edition=fundamental","pubTime":"2025-03-06 04:38","pubTimestamp":1741207106,"startTime":"0","endTime":"0","summary":"ASX:OPT Earnings and Revenue History March 5th 2025. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Biotechs industry in Australia.The company's shares are down 18% from a week ago.You still need to take note of risks, for example - Opthea has   4 warning signs   we think you should be aware of.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-first-half-2025-earnings-203826235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPT.AU","OPT"],"gpt_icon":1},{"id":"2516364524","title":"Opthea Says Trial Data for Eye Disease Drug Candidate Published in Peer-Reviewed Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364524","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516364524?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:43","pubTimestamp":1740966234,"startTime":"0","endTime":"0","summary":"Opthea  announced the publication of data from a phase 2b trial of its sozinibercept drug candidate for wet age-related macular degeneration in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina, according to a Monday Australian bourse filing.The paper reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-nave patients.The randomized, controlled trial saw sozinibercept combination therapy leading to superior visual gains compared to therapy with only ranibizumab at 24 weeks.Analysis of the data showed that in patients with occult and minimally classic lesions, representing 73% of the Phase 2b total patient population, sozinibercept combination therapy demonstrated a \"statistically significant\" gain in best corrected visual acuity compared to ranibizumab alone.Opthea's shares rose almost 3% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT","BK7067","BK7508","OPT.AU"],"gpt_icon":0},{"id":"2514585323","title":"Press Release: Opthea Reports Half Year Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514585323","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514585323?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744000,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents of $131.9M as of December 31, 2024. Cash runway extends through anticipated topline data readouts of COAST  and ShORe . \"Opthea is making significant progress on its mission to deliver superior vision to patients with wet AMD enabling them to live fuller and healthier lives,\" said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. \"Sozinibercept has the potential to be the first product in nearly 20 years to demonstrate superior visual outcomes in combination with standard of care therapy, and we look forward to the anticipated topline data readouts of our two Phase 3 clinical trials in early Q2 and mid-calendar year 2025.\". Tom Reilly, Chief Financial Officer of Opthea, added: \"Looking ahead, we expect our cash and cash equivalents to fund the Company through the anticipated topline data readouts of the Phase 3 COAST and ShORe trials. In addition, we continue to progress our manufacturing  activities as we prepare our Biologics License Application  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","LU0719512351.SGD","LU2098885051.SGD","BK4585","LU1316542783.SGD","LU1951198990.SGD","LU0642271901.SGD","LU2458330243.SGD","LU1303367103.USD","IE00BHPRN162.USD","BK4573","BK4139","LU1852331112.SGD","LU1951200564.SGD","BK4575","IE00B5949003.HKD","IE00BMPRXN33.USD","CMC","LU0149725797.USD","BK4006","LU0823421416.USD","LU1880398471.USD","LU1989764664.SGD","BK4529","LU0170899867.USD","LU2458330169.SGD","LU0127658192.USD","BK4566","LU2250418816.HKD","BK4141","BK7067","LU0056508442.USD","LU0823421333.USD","LU1803068979.SGD","LU0823434583.USD","BK4532","LU0889565833.HKD","IE00BKVL7J92.USD","LU1923623000.USD","BK4543","IE00BMPRXR70.SGD","LU0971096721.USD","LU0390134368.USD","LU0979878070.USD","LU2360106780.USD","OPT","IE0009356076.USD","OPT.AU","GFS"],"gpt_icon":1},{"id":"2514357685","title":"Opthea Posts Narrower Fiscal H1 Loss, Lower Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2514357685","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514357685?lang=en_us&edition=fundamental","pubTime":"2025-02-28 08:02","pubTimestamp":1740700931,"startTime":"0","endTime":"0","summary":"Opthea  reported Friday that its loss per diluted share in the fiscal first half narrowed to $0.108 from $0.172 a year earlier.Analysts polled by Visible Alpha were expecting a loss of $0.14 per diluted share.Total revenue for the six months ended Dec. 31, 2024, was $149,000, down from $202,000 in the same period a year earlier. Analysts surveyed by Visible Alpha expected $100,000.Company shares were down 2% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","OPT"],"gpt_icon":0},{"id":"2514333353","title":"BRIEF-Opthea Says HY Loss From Ordinary Activities Before Tax Increased To $137.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514333353?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:24","pubTimestamp":1740691497,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Says HY Loss From Ordinary Activities Before Tax Increased To $137.9 MillionFeb 28  - Opthea Ltd OPT.AX:HY LOSS FROM ORDINARY ACTIVITIES BEFORE TAX INCREASED 29% TO $137.9 MILLION HY REVENUES FROM ORDINARY ACTIVITIES $24,000Further company coverage: OPT.AX  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI378:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2514584013","title":"Corrected-Opthea Ltd - Hy Loss From Ordinary Activities Before Tax Increased 29% to $137.9 Mln (Corrects Currency to $ From a$)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514584013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514584013?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:24","pubTimestamp":1740691496,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI378:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OPT.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":74}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPT.AU\",market:\"AU\",,,undefined,":[]}}